Insider transactions

EDGAR

Encompass Health Corporation

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-22.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
18 transactions, 404,109 shares
Sum of shares × price per share: 47,785,596.88

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 122

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-19 Filed 2026-10-19Christie Edward M III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)221126.63
27,985.23

Derived: shares × price per share. Exact value 27985.23.

9,577Direct (D) No
F2, F3
  • F2 The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.21 per share paid on October 15, 2026.
  • F3 This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $126.62 to $126.73, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.
Open filing 0000785161-26-000224 Read from the filing’s XML Dispute this row
2026-10-19 Filed 2026-10-19Reidy Christopher R Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)284126.89
36,036.76

Derived: shares × price per share. Exact value 36036.76.

18,081Direct (D) No
F2, F3
  • F2 The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.21 per share paid on October 15, 2026.
  • F3 This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $126.83 to $126.89, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.
Open filing 0000785161-26-000223 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-19Christie Edward M III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)110—9,356Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2026, Encompass Health paid a dividend on its common stock of $0.21 per share and the closing price was $127.77. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000224 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-19Williams Terrance Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)280—16,887Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2026, Encompass Health paid a dividend on its common stock of $0.21 per share and the closing price was $127.77. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000231 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-19HERMAN JOAN E Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)810—49,724Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2026, Encompass Health paid a dividend on its common stock of $0.21 per share and the closing price was $127.77. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000225 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-19KATZ LESLYE G Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)810—49,724Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2026, Encompass Health paid a dividend on its common stock of $0.21 per share and the closing price was $127.77. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000220 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-19O'Connor Kevin J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)180—11,600Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2026, Encompass Health paid a dividend on its common stock of $0.21 per share and the closing price was $127.77. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000221 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-19CARMICHAEL GREG D Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)280—20,377Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2026, Encompass Health paid a dividend on its common stock of $0.21 per share and the closing price was $127.77. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000232 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-19Reidy Christopher R Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)200—17,797Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2026, Encompass Health paid a dividend on its common stock of $0.21 per share and the closing price was $127.77. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000223 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-19SCHLICHTING NANCY M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)380—23,010Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2026, Encompass Health paid a dividend on its common stock of $0.21 per share and the closing price was $127.77. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000226 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-19Hayes Cain A Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)40—2,100Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2026, Encompass Health paid a dividend on its common stock of $0.21 per share and the closing price was $127.77. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000222 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-01Darby John Patrick Officer: EVP, Gen Counsel Secretary
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Encompass Health Common Stock
Acquired (A)4,85835.06
170,321.48

Derived: shares × price per share. Exact value 170321.48.

79,899Direct (D) No— Open filing 0000785161-26-000208 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-01Darby John Patrick Officer: EVP, Gen Counsel Secretary
S

Open market or private sale of non-derivative or derivative security

Encompass Health Common Stock
Disposed (D)4,858121.09
588,255.22

Derived: shares × price per share. Exact value 588255.22.

75,041Direct (D) No— Open filing 0000785161-26-000208 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-01Darby John Patrick Officer: EVP, Gen Counsel Secretary
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Non-qualified Stock Option (Right to Buy) — underlying Encompass Health Common Stock (4,858) — exercise price 35.06
Disposed (D)4,8580—0Direct (D) No
F1
  • F1 The exercise price and number of options reported have been adjusted, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc
Open filing 0000785161-26-000208 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-01Price Andrew L Officer: Chief Accounting Officer
S

Open market or private sale of non-derivative or derivative security

Encompass Health Common Stock
Disposed (D)5,211120.93
630,166.23

Derived: shares × price per share. Exact value 630166.23.

69,483Direct (D) No— Open filing 0000785161-26-000209 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-11Darby John Patrick Officer: EVP, Gen Counsel Secretary
S

Open market or private sale of non-derivative or derivative security

Encompass Health Common Stock
Disposed (D)8,906125.95
1,121,710.7

Derived: shares × price per share. Exact value 1121710.70.

75,041Direct (D) No
F1
  • F1 This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.94 to $126.04, inclusive. The reporting pers on undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
Open filing 0000785161-26-000190 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-11Tarr Mark J Director · Officer: President CEO
S

Open market or private sale of non-derivative or derivative security

Encompass Health Common Stock
Disposed (D)171,569125.46
21,525,046.74

Derived: shares × price per share. Exact value 21525046.74.

269,393Direct (D) No
F1
  • F1 This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.93 to $125.92, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
Open filing 0000785161-26-000191 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-11Tarr Mark J Director · Officer: President CEO
S

Open market or private sale of non-derivative or derivative security

Encompass Health Common Stock
Disposed (D)1,579126.06
199,048.74

Derived: shares × price per share. Exact value 199048.74.

267,814Direct (D) No
F2
  • F2 This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.93 to $126.22, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
Open filing 0000785161-26-000191 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-11COLTHARP DOUGLAS E Officer: EVP Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Encompass Health Common Stock
Disposed (D)18,869125.38
2,365,795.22

Derived: shares × price per share. Exact value 2365795.22.

50,508Direct (D) No
F1
  • F1 This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.03 to $125.69, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
Open filing 0000785161-26-000192 Read from the filing’s XML Dispute this row
2026-07-16 Filed 2026-07-16Reidy Christopher R Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)319112.40
35,855.6

Derived: shares × price per share. Exact value 35855.60.

17,777Direct (D) No
F2
  • F2 The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on July 15, 2026.
Open filing 0000785161-26-000180 Read from the filing’s XML Dispute this row
2026-07-16 Filed 2026-07-16Christie Edward M III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)248112.43
27,882.64

Derived: shares × price per share. Exact value 27882.64.

9,345Direct (D) No
F2, F3
  • F2 The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on July 15, 2026.
  • F3 This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $112.40 to $112.43, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.
Open filing 0000785161-26-000178 Read from the filing’s XML Dispute this row
2026-07-15 Filed 2026-07-16Williams Terrance Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)290—16,859Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000176 Read from the filing’s XML Dispute this row
2026-07-15 Filed 2026-07-16Reidy Christopher R Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)210—17,458Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000180 Read from the filing’s XML Dispute this row
2026-07-15 Filed 2026-07-16SCHLICHTING NANCY M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)400—22,972Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000174 Read from the filing’s XML Dispute this row
2026-07-15 Filed 2026-07-16Hayes Cain A Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)40—2,096Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000166 Read from the filing’s XML Dispute this row
2026-07-15 Filed 2026-07-16KATZ LESLYE G Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)850—49,643Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000170 Read from the filing’s XML Dispute this row
2026-07-15 Filed 2026-07-16HERMAN JOAN E Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)850—49,643Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000168 Read from the filing’s XML Dispute this row
2026-07-15 Filed 2026-07-16Christie Edward M III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)110—9,097Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000178 Read from the filing’s XML Dispute this row
2026-07-15 Filed 2026-07-16O'Connor Kevin J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)190—11,582Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000172 Read from the filing’s XML Dispute this row
2026-07-15 Filed 2026-07-16CARMICHAEL GREG D Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)290—20,349Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Open filing 0000785161-26-000164 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-18COLTHARP DOUGLAS E Officer: EVP Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Encompass Health Common Stock
Acquired (A)27,69432.94
912,240.36

Derived: shares × price per share. Exact value 912240.36.

97,071Direct (D) No— Open filing 0000785161-26-000158 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-18COLTHARP DOUGLAS E Officer: EVP Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Encompass Health Common Stock
Disposed (D)27,693106.83
2,958,443.19

Derived: shares × price per share. Exact value 2958443.19.

69,378Direct (D) No
F1
  • F1 This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.28 to $107.22, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.
Open filing 0000785161-26-000158 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-18COLTHARP DOUGLAS E Officer: EVP Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Encompass Health Common Stock
Disposed (D)1107.28
107.28

Derived: shares × price per share. Exact value 107.28.

69,377Direct (D) No— Open filing 0000785161-26-000158 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-18COLTHARP DOUGLAS E Officer: EVP Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Non-qualified Stock Option (Right to Buy) — underlying Encompass Health Common Stock (27,694) — exercise price 32.94
Disposed (D)27,6940—0Direct (D) No
F2
  • F2 The exercise price and number of options reported have been adjusted, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.
Open filing 0000785161-26-000158 Read from the filing’s XML Dispute this row
2026-05-11 Filed 2026-05-12Tuer Patrick William Officer: EVP, Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Encompass Health Common Stock
Disposed (D)682104.56
71,309.92

Derived: shares × price per share. Exact value 71309.92.

24,755Direct (D) No— Open filing 0000785161-26-000153 Read from the filing’s XML Dispute this row
2026-05-07 Filed 2026-05-11Christie Edward M III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)1,6340—9,086Direct (D) No
F1
  • F1 Annual grant of restricted stock units pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.
Open filing 0000785161-26-000146 Read from the filing’s XML Dispute this row
2026-05-07 Filed 2026-05-11O'Connor Kevin J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)1,6340—11,563Direct (D) No
F1
  • F1 Annual grant of restricted stock units pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.
Open filing 0000785161-26-000148 Read from the filing’s XML Dispute this row
2026-05-07 Filed 2026-05-11Hayes Cain A Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)1,6340—2,092Direct (D) No
F1
  • F1 Annual grant of restricted stock units pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.
Open filing 0000785161-26-000142 Read from the filing’s XML Dispute this row
2026-05-07 Filed 2026-05-11KATZ LESLYE G Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)1,6340—49,558Direct (D) No
F1
  • F1 Annual grant of restricted stock units pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.
Open filing 0000785161-26-000136 Read from the filing’s XML Dispute this row
2026-05-07 Filed 2026-05-11Williams Terrance Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)1,6340—16,830Direct (D) No
F1
  • F1 Annual grant of restricted stock units pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.
Open filing 0000785161-26-000138 Read from the filing’s XML Dispute this row
2026-05-07 Filed 2026-05-11SCHLICHTING NANCY M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)1,6340—22,932Direct (D) No
F1
  • F1 Annual grant of restricted stock units pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.
Open filing 0000785161-26-000132 Read from the filing’s XML Dispute this row
2026-05-07 Filed 2026-05-11CARMICHAEL GREG D Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)1,6340—20,320Direct (D) No
F1
  • F1 Annual grant of restricted stock units pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.
Open filing 0000785161-26-000140 Read from the filing’s XML Dispute this row
2026-05-07 Filed 2026-05-11Reidy Christopher R Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)1,6340—17,437Direct (D) No
F1
  • F1 Annual grant of restricted stock units pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.
Open filing 0000785161-26-000144 Read from the filing’s XML Dispute this row
2026-05-07 Filed 2026-05-11HERMAN JOAN E Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)1,6340—49,558Direct (D) No
F1
  • F1 Annual grant of restricted stock units pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.
Open filing 0000785161-26-000134 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-16Christie Edward M III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)261106.17
27,710.37

Derived: shares × price per share. Exact value 27710.37.

7,452Direct (D) No
F2, F3
  • F2 The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on April 15, 2026.
  • F3 This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.11 to $106.17, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.
Open filing 0000785161-26-000123 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-16Reidy Christopher R Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)334106.48
35,564.32

Derived: shares × price per share. Exact value 35564.32.

15,803Direct (D) No
F2, F3
  • F2 The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on April 15, 2026.
  • F3 This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.21 to $106.48, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.
Open filing 0000785161-26-000113 Read from the filing’s XML Dispute this row
2026-04-15 Filed 2026-04-16Christie Edward M III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)90—7,191Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $105.24. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.
Open filing 0000785161-26-000123 Read from the filing’s XML Dispute this row
2026-04-15 Filed 2026-04-16O'Connor Kevin J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)170—9,929Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $105.24. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.
Open filing 0000785161-26-000115 Read from the filing’s XML Dispute this row
2026-04-15 Filed 2026-04-16Hayes Cain A Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)10—458Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $105.24. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.
Open filing 0000785161-26-000121 Read from the filing’s XML Dispute this row
2026-04-15 Filed 2026-04-16Williams Terrance Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Encompass Health Common Stock
Acquired (A)270—15,196Direct (D) No
F1
  • F1 Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units (RSUs) are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $105.24. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.
Open filing 0000785161-26-000109 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–50 of 645

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
BlackRock, Inc. Partly reported under another manager10,453,284 SH1,269,969,421 dollarsLower by 31,101 Prior quarter: 10,484,385Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager5,498,786 SH668,049 dollarsHigher by 442,985 Prior quarter: 5,055,801Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 4,897,787 SH595,032,143 dollarsLower by 26,877 Prior quarter: 4,924,664Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 4,418,093 SH536,754,119 dollarsLower by 57,803 Prior quarter: 4,475,896Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
STATE STREET CORP Partly reported under another manager3,190,852 SH387,656,609 dollarsHigher by 5,054 Prior quarter: 3,185,798Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
FULLER THALER ASSET MANAGEMENT, INC. 2,721,226 SH330,601,787 dollarsHigher by 260,569 Prior quarter: 2,460,657Open filing 0001420506-26-002692 Filed 2026-11-13 Dispute this row
AMERICAN CENTURY COMPANIES INC Partly reported under another manager2,598,892 SH315,740,540 dollarsHigher by 1,548,422 Prior quarter: 1,050,470Open filing 0000748054-26-000009 Filed 2026-11-20 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager2,554,703 SH310,370,867 dollarsLower by 8,401 Prior quarter: 2,563,104Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager1,922,285 SH233,556,401 dollarsHigher by 179,257 Prior quarter: 1,743,028Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
ALLIANCEBERNSTEIN L.P. Partly reported under another manager1,891,554 SH229,804,984 dollarsLower by 580,197 Prior quarter: 2,471,751Open filing 0001109448-26-000342 Filed 2026-11-16 Dispute this row
WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager1,880,700 SH228,486,243 dollarsLower by 1,398,039 Prior quarter: 3,278,739Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager1,847,000 SH224,448,211 dollarsLower by 43,743 Prior quarter: 1,890,743Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
MILLENNIUM MANAGEMENT LLC 1,587,198 SH192,828,685 dollarsHigher by 781,481 Prior quarter: 805,717Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
TWO SIGMA INVESTMENTS, LP 1,581,676 SH192,157,817 dollarsLower by 685,992 Prior quarter: 2,267,668Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
RAYMOND JAMES FINANCIAL INC Partly reported under another manager1,345,548 SH163,470,556 dollarsHigher by 281,315 Prior quarter: 1,064,233Open filing 0000720005-26-000081 Filed 2026-11-12 Dispute this row
Boston Partners Partly reported under another manager1,300,859 SH158,052,800 dollarsNot in the prior quarter’s filings read Open filing 0001386060-26-000054 Filed 2026-11-10 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager1,285,969 SH156,232,366 dollarsLower by 264,828 Prior quarter: 1,550,797Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP Partly reported under another manager1,234,666 SH149,999,572 dollarsHigher by 77,736 Prior quarter: 1,156,930Open filing 0001164508-26-000060 Filed 2026-11-13 Dispute this row
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1,166,552 SH141,724,402 dollarsHigher by 15,467 Prior quarter: 1,151,085Open filing 0001644956-26-000031 Filed 2026-11-06 Dispute this row
Allspring Global Investments Holdings, LLC Partly reported under another manager1,096,357 SH130,532,272 dollarsHigher by 827,982 Prior quarter: 268,375Open filing 0001890906-26-000078 Filed 2026-11-04 Dispute this row
Eversept Partners, LP 1,082,316 SH131,490,571 dollarsHigher by 55,397 Prior quarter: 1,026,919Open filing 0001697013-26-000007 Filed 2026-11-16 Dispute this row
Holocene Advisors, LP 1,050,410 SH127,614,311 dollarsHigher by 72,776 Prior quarter: 977,634Open filing 0001172661-26-005338 Filed 2026-11-16 Dispute this row
BROWN ADVISORY INC Partly reported under another manager1,006,251 SH122,249,507 dollarsLower by 6,480 Prior quarter: 1,012,731Open filing 0001345929-26-000049 Filed 2026-11-16 Dispute this row
Capital Research Global Investors Partly reported under another manager989,783 SH120,248,737 dollarsHigher by 117,243 Prior quarter: 872,540Open filing 0001422848-26-000129 Filed 2026-11-12 Dispute this row
Invesco Ltd. Partly reported under another manager971,775 SH118,060,944 dollarsLower by 189,333 Prior quarter: 1,161,108Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager947,549 SH115,117,729 dollarsLower by 23,135 Prior quarter: 970,684Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager940,778 SH116,928,743 dollarsLower by 192,783 Prior quarter: 1,133,561Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
MORGAN STANLEY Partly reported under another manager916,679 SH111,367,540 dollarsLower by 230,194 Prior quarter: 1,146,873Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager898,782 SH109,193,038 dollarsHigher by 110,692 Prior quarter: 788,090Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
Sumitomo Mitsui Trust Group, Inc. Partly reported under another manager861,915 SH104,714,053 dollarsLower by 68,415 Prior quarter: 930,330Open filing 0001214659-26-013361 Filed 2026-10-29 Dispute this row
LOS ANGELES CAPITAL MANAGEMENT LLC 848,149 SH103,041,623 dollarsHigher by 299,324 Prior quarter: 548,825Open filing 0001177206-26-000010 Filed 2026-11-12 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager819,695 SH99,584,785 dollarsHigher by 11,661 Prior quarter: 808,034Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
Thrivent Financial for Lutherans Partly reported under another manager777,380 SH94,281 dollarsHigher by 71,783 Prior quarter: 705,597Open filing 0001193125-26-449292 Filed 2026-11-05 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 724,020 SH87,961,190 dollarsHigher by 35,756 Prior quarter: 688,264Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
Copeland Capital Management, LLC Partly reported under another manager713,677 SH86,704,831 dollarsLower by 141,738 Prior quarter: 855,415Open filing 0001580642-26-006863 Filed 2026-10-13 Dispute this row
Zurcher Kantonalbank (Zurich Cantonalbank) Partly reported under another manager631,860 SH76,764,671 dollarsHigher by 203,720 Prior quarter: 428,140Open filing 0001368163-26-000007 Filed 2026-11-10 Dispute this row
Woodline Partners LP 628,976 SH76,414,294 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 625,524 SH75,994,911 dollarsLower by 2,230 Prior quarter: 627,754Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
JENNISON ASSOCIATES LLC Partly reported under another manager625,510 SH75,993,209 dollarsHigher by 18,748 Prior quarter: 606,762Open filing 0000053417-26-000068 Filed 2026-11-16 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager620,012 SH87,440,292 dollarsHigher by 21,527 Prior quarter: 598,485Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
SEI INVESTMENTS CO Partly reported under another manager562,663 SH68,357,077 dollarsHigher by 149,669 Prior quarter: 412,994Open filing 0000350894-26-000059 Filed 2026-11-10 Dispute this row
VICTORY CAPITAL MANAGEMENT INC 490,641 SH59,607,975 dollarsHigher by 96,252 Prior quarter: 394,389Open filing 0001040188-26-000051 Filed 2026-11-10 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager485,406 SH58,959 dollarsLower by 14,454 Prior quarter: 499,860Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
SILVERCREST ASSET MANAGEMENT GROUP LLC 441,163 SH53,597,070 dollarsHigher by 147,489 Prior quarter: 293,674Open filing 0001193125-26-462346 Filed 2026-11-16 Dispute this row
SYSTEMATIC FINANCIAL MANAGEMENT LP Partly reported under another manager425,431 SH51,685,821 dollarsLower by 17,709 Prior quarter: 443,140Open filing 0001398344-26-020097 Filed 2026-11-16 Dispute this row
REINHART PARTNERS, LLC. 404,257 SH49,113,183 dollarsLower by 31,105 Prior quarter: 435,362Open filing 0001080298-26-000010 Filed 2026-10-09 Dispute this row
Allianz Asset Management GmbH Partly reported under another manager399,691 SH48,558,458 dollarsLower by 302,269 Prior quarter: 701,960Open filing 0001193125-26-463640 Filed 2026-11-16 Dispute this row
CONGRESS ASSET MANAGEMENT CO 396,336 SH48,150,848 dollarsLower by 9,785 Prior quarter: 406,121Open filing 0000897378-26-000015 Filed 2026-10-06 Dispute this row
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. Partly reported under another manager388,154 SH47,149,680 dollarsLower by 55,023 Prior quarter: 443,177Open filing 0000905148-26-004861 Filed 2026-11-16 Dispute this row
ENVESTNET ASSET MANAGEMENT INC 366,975 SH44,583,757 dollarsLower by 2,022 Prior quarter: 368,997Open filing 0001214659-26-014231 Filed 2026-11-16 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • NORGES BANK 1,154,864 SH
  • Sixth Street Partners Management Company, L.P. 688,264 SH
  • D. E. Shaw Co., Inc. 384,595 SH
  • HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 206,166 SH
  • SG Americas Securities, LLC 159,367 SH
  • HRT FINANCIAL LP 155,554 SH
  • Curated Wealth Partners LLC 70,343 SH
  • Longaeva Partners L.P. 70,000 SH
  • Jupiter Topco LLC 45,258 SH
  • Avidity Partners Management LP 42,000 SH
  • Verition Fund Management LLC 40,000 SH
  • CAPITAL FUND MANAGEMENT S.A. 34,005 SH
  • TWINBEECH CAPITAL LP 33,566 SH
  • Seascape Capital Management 31,122 SH
  • OCCUDO QUANTITATIVE STRATEGIES LP 28,054 SH
  • Engineers Gate Manager LP 26,953 SH
  • Walleye Trading LLC 25,200 SH
  • Elo Mutual Pension Insurance Co 17,795 SH
  • Summit Trail Advisors, LLC 16,187 SH
  • Qsemble Capital Management, LP 14,751 SH
  • Campbell CO Investment Adviser LLC 13,703 SH
  • Envestnet Portfolio Solutions, Inc. 13,571 SH
  • Arkadios Wealth Advisors 13,356 SH
  • Dynamic Technology Lab Private Ltd 12,439 SH
  • Wellington Shields Co., LLC 12,330 SH
  • Illinois Municipal Retirement Fund 11,624 SH
  • Pacer Advisors, Inc. 11,050 SH
  • EntryPoint Capital, LLC 8,113 SH
  • Scientech Research LLC 6,709 SH
  • Centiva Capital, LP 6,599 SH
  • Numerai GP LLC 6,077 SH
  • FOX RUN MANAGEMENT, L.L.C. 5,977 SH
  • LANDSCAPE CAPITAL MANAGEMENT, L.L.C. 5,944 SH
  • MANGROVE PARTNERS IM, LLC 5,537 SH
  • Virtu Financial LLC 5,139 SH
  • NewEdge Wealth, LLC 5,113 SH
  • SIG BROKERAGE, LP 5,000 SH
  • SIG BROKERAGE, LP 5,000 SH
  • Weiss Asset Management LP 3,603 SH
  • OXFORD ASSET MANAGEMENT LLP 3,563 SH
  • 111 Capital 3,035 SH
  • Blueshift Asset Management, LLC 2,933 SH
  • AlphaGrep UK Ltd 2,880 SH
  • Wealthspire Advisors, LLC 2,435 SH
  • Gibson Capital, LLC 2,431 SH
  • SIG BROKERAGE, LP 2,421 SH
  • MARSHALL WACE, LLP 2,227 SH
  • JOHNSON INVESTMENT COUNSEL INC 2,186 SH
  • HIGHLAND CAPITAL MANAGEMENT, LLC 2,035 SH
  • Graticule Asia Macro Advisors LLC 1,878 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

Showing 1–9 of 9

House members’ trades in this company, newest report first, as filed
MemberTransaction dateTypeAmountOwnerReport
Hon. Lisa McClain (MI09)2025-10-30Purchase$1,001 - $15,000SP2025-11-21
Hon. Lisa McClain (MI09)2025-10-30Sale$1,001 - $15,000SP2025-11-21
Hon. Lisa McClain (MI09)2025-10-31Sale$1,001 - $15,000SP2025-11-21
Hon. Lisa McClain (MI09)2025-07-22Purchase$1,001 - $15,000SP2025-08-13
Mr. Peter Meijer (MI03)2021-02-16Sale$1,001 - $15,0002021-03-16
Hon. Susie Lee (NV03)2020-08-27Sale$1,001 - $15,000JT2020-10-07
Hon. Susie Lee (NV03)2020-05-19Purchase$1,001 - $15,000JT2020-06-15
Hon. Susie Lee (NV03)2019-07-31Sale$1,001 - $15,000JT2019-08-29
Hon. Susie Lee (NV03)2019-03-15Purchase$1,001 - $15,000JT2019-04-08

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
T. Rowe Price Associates, Inc. COMMON STOCK5.15,056,22506/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0000080255-26-000523 Dispute this row
Vanguard Portfolio Management Common Stock4.974,935,74806/30/2026 Filed 2026-07-31SCHEDULE 13G/AAmendment 1Open filing 0002100121-26-000896 Dispute this row
Vanguard Portfolio Management Common Stock54,971,60103/31/2026 Filed 2026-04-29SCHEDULE 13GOpen filing 0002100121-26-000266 Dispute this row
Vanguard Capital Management Common Stock5.265,233,62203/31/2026 Filed 2026-04-29SCHEDULE 13GOpen filing 0002100119-26-000471 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 13Open filing 0000102909-26-001158 Dispute this row
Invesco Ltd. Common Stock4.94,972,725.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 1Open filing 0000914208-26-000036 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,762,359 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015178,741
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to Encompass Health Corporation